

Manufacturer's Declaration

in relation to Regulation (EU) 2024/1860 amending Regulation (EU) 2017/746 (IVDR) as regards the transitional provisions for certain *in vitro* diagnostic medical devices, in particular with respect to

- the extended transitional periods for devices for which the conformity assessment procedure pursuant to Directive 98/79/EC (IVDD) did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2022 and for which the conformity assessment procedure pursuant to Regulation (EU) 2017/746 (IVDR) requires the involvement of a notified body *and/or*
- the validity of certificates issued under Directive 98/79/EC (IVDD) (Directive Certificate) *and/or*
- the compliance of the devices and us, as their manufacturer, with the conditions for the continued placing on the market and putting into service

Manufacturer name	National Health Service Blood & Transplant (NHSBT)
Manufacturer address and contact details	Address: 14 Estuary Banks, Liverpool, L24 SRB, United Kingdom Contact details: Michelle Weston Reagents Manager +44(0)151 2687160 michelle.weston@nhsbt.nhs.uk
Single Registration Number (SRN) (if available)	Not available

Authorised Representative name (if applicable)	Quality First International OÜ Laki 30 12915 Tallinn Estonia
Authorised Representative address and contact details	Address: Laki 30, 2915 Tallinn, Estonia Contact details: +44(0)208 221 2361 enquiries@qualityfirstint.com
Single Registration Number (SRN) (if available)	EE-AR-000004308

Blood and Transplant

Notified body name (if applicable)	☒ See attached schedule ☐ Not applicable
Notified body number (if applicable)	☒ See attached schedule ☐ Not applicable
Directive Certificate number(s) to which this confirmation is made (if applicable)	☒ See attached schedule ☐ Not applicable
Original expiry date as indicated on the Directive Certificate(s) prior to the extension of the validity (if applicable)	☒ See attached schedule ☐ Not applicable
End date of extended validity/transition period	☒ See attached schedule

We, as the manufacturer declare under our sole responsibility:

- for the **device(s)** listed in the attached schedule the conditions for the legal extension of transitional periods as required in Article 110.3b of the IVDR are met *and/or*
- for the **Directive Certificate(s)** listed in the attached schedule the conditions for the legal extension of validity as required in Article 110.2 of the IVDR are met *and/or*
- the **device(s)** listed in the attached schedule and we as their manufacturer are in compliance with the conditions listed in Article 110.3c of the IVDR for continued placing on the market and putting into service,

namely by fulfilling the following conditions:

➤ **Devices which were self-declared under the IVDD and require notified body involvement under the IVDR**

In case of devices for which the conformity assessment procedure pursuant to IVDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2022 and for which the conformity assessment procedure pursuant to IVDR requires the involvement of a notified body:

Choose one applicable statement:

☐ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII IVDR for conformity assessment has/have been lodged or will be lodged by us to a notified body for the device(s) listed in the attached schedule or its/their substitutes no later than:

- ☐ 26 May 2025 for class D devices
- ☐ 26 May 2026 for class C devices
- ☐ 27 May 2027 for class B and class A (sterile) devices

Blood and Transplant

☐ Signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII IVDR for the device(s) listed in the attached schedule or its/their substitutes no later than:

☐ 26 September 2025 for class D devices

☐ 26 September 2026 for class C devices

☐ 27 September 2027 for class B and class A (sterile) devices

☐ We do not intend to lodge an application for conformity for the device as indicated on the attached schedule.

➤ **Directive Certificate(s)** as listed above or in the attached schedule

- Directive Certificate(s) covering the device(s) listed in the attached schedule was/were issued after 25 May 2017, was/were valid on 26 May 2022 and has/have not been withdrawn afterwards.

Choose applicable statements:

☐ Original expiry date *before 9 July 2024*:

☐ Before the original date of expiry as indicated on the Directive Certificate(s), we and the notified body have signed written agreement(s) in accordance with Section 4.3, second subparagraph of Annex VII IVDR for the conformity assessment(s) in respect of the device(s) covered by the expired certificate(s) or in respect of its/their substitute(s), or

☐ Competent Authority has granted a derogation from the applicable conformity assessment procedure in accordance with Article 54(1) IVDR (may be provided upon request), or

☐ Competent Authority has required us as the manufacturer, in accordance with Article 92(1) IVDR, to carry out the applicable conformity assessment procedure (may be provided upon request)

Choose one of the following statements only if a derogation per Article 54(1) or a requirement per Article 92(1) has been granted by a Competent Authority:

☐ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII IVDR for conformity assessment has/have been lodged or will be lodged by us to a notified body no later than 26 May 2025 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII IVDR before 26 September 2025.

☐ We do not intend to lodge an application for conformity assessment by 26 May 2025, therefore the transition period will end on 26 May 2025.

☒ Original expiry date *after 9 July 2024*:

Choose one applicable statement:

☒ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII IVDR for conformity assessment has/have been lodged or will be lodged by us to a notified body no later than 26 May 2025 for the device(s) listed in the attached

Blood and Transplant

schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII IVDR before 26 September 2025.

- ☐ We do not intend to lodge an application for conformity assessment by 26 May 2025 for the devices as indicated on the attached schedule, therefore the transition period will end on 26 May 2025.
- ☐ assessment by 26 May 2025, therefore the transition period will end on 26 May 2025.

➤ **Quality Management System (QMS)**

Choose one applicable statement:

- ☐ QMS in accordance with Article 10(8) IVDR will be put in place by no later than 26 May 2025.
- ☒ QMS in accordance with Article 10(8) IVDR is in place.
- ☐ Notified body has issued the attached certificate for the IVDR-compliant QMS.

➤ **Device(s) listed in the attached schedule (apart from the device indicated to be withdrawn)**

- The device(s) continue(s) to comply with the IVDD.
- There are no significant changes in the design and intended purpose.
- The device(s) do not present an unacceptable risk to health or safety of patients, users or other persons, or to other aspects of the protection of public health.

Signed for and on behalf of the manufacturer:

Full Company Name – National Health Service Blood & Transplant (NHSBT)

Location – 14 Estuary Banks, Liverpool, L24 SRB, United Kingdom

Date – 23/05/2025

Signature – 

Print Name – Jeremy Kellington

Title – Lead Quality Specialist, Person Responsible for Regulatory Compliance

Contact Details (at least email) – jeremy.kellington@nhsbt.nhs.uk

Schedule of Devices

The above Manufacturer's Declaration is valid for the following devices:

Identification of the device(s)¹ (e.g., device name, family/group name, device model or catalogue number)	End date of extended validity / transition period	Substitute Device(s) (if applicable)	Directive Certificate number to which this declaration is issued (if applicable)	Original expiry date as indicated on the Directive Certificate prior to the extension of the validity (if applicable)	Notified Body name and number that issued the Directive Certificate (if applicable)	Notified Body name and number where the IVDR application was lodged/contract signed (if applicable)
A1rr cells in Alsevers (10 ml 2.8% suspension) PR012	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
A2rr cells in Alsevers (10 ml 2.8% suspension) PR022	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Brr cells in Alsevers (10 ml 2.8% suspension) PR033	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
OR1r cells in Alsevers (10 ml 2.8% suspension) PR044	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
A1 rr cells in CellStab (10 ml 0.8% suspension) PR014	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797

¹ for devices with IVDD certificate(s) the identification should be as in the certificate, and only if the certificate has a generic scope it should be as defined above

Blood and Transplant

A1 rr cells in CellMedia (10 ml 0.8% suspension) PR015	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Brr cells in CellStab (10 ml 0.8% suspension) PR035	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Brr cells in CellMedia (10 ml 0.8% suspension) PR036	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
BR1 r cells in Alsevers (10 ml 2.8% suspension) PR034	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
OR1r cells in CellStab (10 ml 0.8% suspension) PR045	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
OR1 r cells in CellMedia (10 ml 0.8% suspension) PR046	31.12.2027	N/A	1434-IVDD-131/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
A1rr cells in Alsevers (10 ml 2.8% suspension) PR012	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
A2rr cells in Alsevers (10 ml 2.8% suspension) PR022	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Brr cells in Alsevers (10 ml 2.8% suspension) PR033	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797

Blood and Transplant

OR1r cells in Alsevers (10 ml 2.8% suspension) PR044	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
A1 rr cells in CellStab (10 ml 0.8% suspension) PR014	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
A1 rr cells in CellMedia (10 ml 0.8% suspension) PR015	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Brr cells in CellStab (10 ml 0.8% suspension) PR035	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Brr cells in CellMedia (10 ml 0.8% suspension) PR036	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
BR1 r cells in Alsevers (10 ml 2.8% suspension) PR034	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
OR1r cells in CellStab (10 ml 0.8% suspension) PR045	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
OR1 r cells in CellMedia (10 ml 0.8% suspension) PR046	31.12.2027	N/A	1434-IVDD-132/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
2 Cell antibody screen PR101	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797

Blood and Transplant

2 Cell antibody screen in CellStab PR102	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
2 Cell antibody screen in CellMedia PR103	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
rr Cell antibody screen in CellStab PR106	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
rr Cell antibody screen in CellMedia PR108	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
r'r and r''r Cell antibody screen in CellStab PR107	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
r'r and r''r Cell antibody screen in CellMedia PR109	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Antibody ID panel products in Alsevers PR141/144/201/211	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Antibody ID panel products in CellStab PR142/143/202/212	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Antibody ID panel products in CellMedia PR162/163	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797

Blood and Transplant

Antibody ID panel products in LISP PR146	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Antibody ID panel products papainised in Alsevers PR154	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Antibody ID panel products papainised in CellStab PR152/153	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Antibody ID panel products papainised in CellMedia PR172/173	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
IgG coated cells PR092	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Weak Anti-K Control PN043	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Weak Anti-c Control PN042	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
Weak Anti-Fya Control PN044	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797

Blood and Transplant

Weak Anti-D Control PN046	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
AB Serum PN061	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
3 Cell antibody screen PR121	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
3 Cell antibody screen in CellStab PR122	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
3 Cell antibody screen in CellMedia PR123	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797
3 Cell antibody screen papainised in Alsevers PR124	31.12.2027	N/A	1434-IVDD-133/2022	27.05.2025	Polskie Centrum Badań i Certyfikacji SA 1434	BSI Group, The Netherlands B.V. 2797